Evidence map›Paper›PMID 31838282›Full record

ArticleJournal of pharmaceutical and biomedical analysis2020

Bioanalytical method development and validation of corynantheidine, a kratom alkaloid, using UPLC-MS/MS, and its application to preclinical pharmacokinetic studies.

Tamara I King, Abhisheak Sharma, Shyam H Kamble, Francisco León, Erin C Berthold, Raluca Popa, Orélia Cerlati, Boone M Prentice, Lance R McMahon, Christopher R McCurdy and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of pharmaceutical and biomedical analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Tamara I KingDepartment of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, 32610, USA.
Abhisheak SharmaDepartment of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, 32610, USA; Translational Drug Development Core, Clinical and Translational Sciences Institute, University of Florida, Gainesville, FL, 32610, USA.
Shyam H KambleDepartment of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, 32610, USA; Translational Drug Development Core, Clinical and Translational Sciences Institute, University of Florida, Gainesville, FL, 32610, USA.
Francisco LeónDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, 32610, USA.
Erin C BertholdDepartment of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, 32610, USA.
Raluca PopaDepartment of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, 32610, USA.
Orélia CerlatiDepartment of Chemistry, University of Florida, Gainesville, FL, 32611, USA.
Boone M PrenticeDepartment of Chemistry, University of Florida, Gainesville, FL, 32611, USA.
Lance R McMahonDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, 32610, USA.
Christopher R McCurdyTranslational Drug Development Core, Clinical and Translational Sciences Institute, University of Florida, Gainesville, FL, 32610, USA; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, 32610, USA. Electronic address: cmccurdy@cop.ufl.edu.
Bonnie A AveryDepartment of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, 32610, USA; Translational Drug Development Core, Clinical and Translational Sciences Institute, University of Florida, Gainesville, FL, 32610, USA.
University of Florida · US

Funding

Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
Opioid use disorders: UF Pharmacy medications discovery and developmentUG3DA048353 · NIDA · UNIVERSITY OF FLORIDA · PI MCCURDY, CHRISTOPHER R, MCMAHON, LANCE R. · 2019 to 2020
$3.6M
Kratom alkaloids: in vitro and in vivo pharmacological mechanismsR01DA047855 · NIDA · UNIVERSITY OF FLORIDA · PI MCCURDY, CHRISTOPHER R, MCMAHON, LANCE R. · 2019 to 2023
$3.6M
NCATS NIH HHS UL1 TR001427NIDA NIH HHS R01 DA047855NIDA NIH HHS UG3 DA048353
6 · The paper itself

Abstract

Corynantheidine, a minor alkaloid found in Mitragyna speciosa (Korth.) Havil, has been shown to bind to opioid receptors and act as a functional opioid antagonist, but its unique contribution to the overall properties of kratom remains relatively unexplored. The first validated bioanalytical method for the quantification of corynantheidine in rat plasma is described. The method was linear in the dynamic range from 1-500 ng/mL, requires a small plasma sample volume (25 μL), and a simple protein precipitation method for extraction of the analyte. The separation was achieved with Waters BEH C18 2.1 × 50 mm column and the 3-minute gradient of 10 mM ammonium acetate buffer (pH = 3.5) and acetonitrile as mobile phase. The method was validated in terms of accuracy, precision, selectivity, sensitivity, recovery, stability, and dilution integrity. It was applied to the analysis of the male Sprague Dawley rat plasma samples obtained during pharmacokinetic studies of corynantheidine administered both intravenously (I.V.) and orally (P.O.) (2.5 mg/kg and 20 mg/kg, respectively). The non-compartmental analysis performed in Certara Phoenix® yielded the following parameters: clearance 884.1 ± 32.3 mL/h, apparent volume of distribution 8.0 ± 1.2 L, exposure up to the last measured time point 640.3 ± 24.0 h*ng/mL, and a mean residence time of 3.0 ± 0.2 h with I.V. dose. The maximum observed concentration after a P.O. dose of 213.4 ± 40.4 ng/mL was detected at 4.1 ± 1.3 h with a mean residence time of 8.8 ± 1.8 h. Absolute oral bioavailability was 49.9 ± 16.4 %. Corynantheidine demonstrated adequate oral bioavailability, prolonged absorption and exposure, and an extensive extravascular distribution. In addition, imaging mass spectrometry analysis of the brain tissue was performed to evaluate the distribution of the compound in the brain. Corynantheidine was detected in the corpus callosum and some regions of the hippocampus.

Indexed as

AlkaloidsAnimalsBiological AvailabilityBiosensing TechniquesBlood Specimen CollectionChromatography, High Pressure LiquidLimit of DetectionMaleMitragynaNarcotic AntagonistsPlant ExtractsRatsRats, Sprague-DawleyReproducibility of ResultsSensitivity and SpecificityTandem Mass SpectrometryAlkaloidshirsutineNarcotic AntagonistsPlant ExtractsAlkaloidCorynantheidineKratomMitragyna speciosaPharmacokineticsUPLC-MS/MS

Identifiers

PMID31838282
PMCPMC7350276
OpenAlexW2992178428

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.